Details of the Drug
General Information of Drug (ID: DM6VCI3)
| Drug Name |
1,10-bis(pyridinium)-decane dibromide
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
P.M. 458; 1,1'-Decamethylenebis(pyridinium bromide); NSC 36864; 6266-40-6; G.L. 110; CHEMBL225689; 1-[10-(pyridin-1-ium-1-yl)decyl]pyridin-1-ium dibromide; Pyridinium, 1,1'-decamethylenebis-, dibromide; 1,10-bis(pyridinium)-decane dibromide; AC1L46P1; MolPort-023-233-174; 1,10-bis(pyridinium)decane dibromide; AKOS033332200; MCULE-1765937122; NE55775; LS-132391; 1,1'-decane-1,10-diyldipyridinium dibromide; Z1424831827; 1-(10-pyridin-1-ium-1-yldecyl)pyridin-1-ium dibromide
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 1 |
Molecular Weight | 458.3 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient | Not Available | ||||||||||||||||||||||
| Rotatable Bond Count | 11 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count | 0 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count | 2 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


